Orchestra BioMed Holdings (OBIO) EBT Margin Growth (1y) (2023 - 2026)

Orchestra BioMed Holdings (OBIO) EBT Margin Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin Growth (1y) (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1,526.00
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1,558.00
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn -683.00
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 813.00
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Orchestra BioMed Holdings 235.83 Mn 141.43 Mn 78,000.00 -2.03 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -2.03 Mn
Dec 31, 2025 638,352.00
Sep 30, 2025 -59,996.00
Jun 30, 2025 65,763.00
Mar 31, 2025 31,500.00
Dec 31, 2024 -170,636.00
Sep 30, 2024 346,972.00
Jun 30, 2024 -138,420.00
Mar 31, 2024 -152,607.00
Dec 31, 2023 -373,546.00
Sep 30, 2023 -435,625.00
Jun 30, 2023 11,450.00
Mar 31, 2023 -40,259.00